Develop new therapies for the treatment of patients with debilitating musculoskeletal disease using uncompromising standards of scientific rigor, personal integrity, and a deep respect for those whose lives we touch.
our focus
Understanding how the dystrophin protein complex protects muscle from injury and strategies to mitigate disease when it is missing or defective such as in Duchenne muscular dystrophy.
learn about our pipeline
program
indications
research
preclinical
POP+
POP+
phase 1
phase 2/3
EDG-5506
EDG-002
EDG-003
Duchenne Muscular Dystrophy (DMD)
Limb Girdle Muscular Dystrophy (LGMD)
Genetically-defined Neuromuscular
and Metabolic Disorders
and Metabolic Disorders
Genetically-defined Cardiac Indications
Current
Year End 2021
+ Proof of Principle, validated in advanced models of disease